Johnson and Johnson

Related Content

Acquisition creates greater opportunity to transform the treatment landscape for cardiovascular disease
News | Cardiovascular Business
Johnson and Johnson Completes Acquisition of Shockwave Medical

May 31, 2024 — Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part ...

Home May 31, 2024
arrow
Mechanical circulatory support boosts survival in cardiogenic shock patients, despite risks
News | Cardiovascular Clinical Studies
Heart Pump Improves Survival After Severe Heart Attacks

April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly ...

Home April 08, 2024
arrow
The acquisition enhances Johnson and Johnson’s ability to transform the treatment landscape for cardiovascular disease and continue to improve patient outcomes
News | Cardiovascular Business
Johnson and Johnson to Acquire Shockwave Medical

April 5, 2024 — Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive ...

Home April 05, 2024
arrow
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. 
News | Balloon Catheter
FDA Announces Medos International SĂ rl Recall of Cerenovus CEREBASE DA Guide Sheath due to Cracking of the Distal Catheter Shaft

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
arrow
Findings from the admIRE study – freedom from atrial arrhythmia recurrence at 12 months – support the submission of the VARIPULSE Platform among U.S. patients
News | Atrial Fibrillation
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
arrow
News | FDA
FDA Approves Johnson & Johnson OPSYNVI (macitentan and tadalafil) Single-Tablet Combination for Patients with Pulmonary Arterial Hypertension (PAH)

March 27, 2024 — Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI – ...

Home March 27, 2024
arrow
Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow
News | Stroke
Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform

March 5, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 05, 2024
arrow
Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation
News | Atrial Fibrillation
Johnson & Johnson MedTech Acquires Laminar, Inc.

November 30, 2023 — Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a ...

Home November 30, 2023
arrow
Study will evaluate the safety and effectiveness of the OMNYPULSE Pulsed Field Ablation (PFA) platform with integrated mapping
News | Cardiovascular Clinical Studies
Biosense Webster Begins Evaluation of Large-tip Focal Pulsed Field Ablation Catheter in Omny-IRE Clinical Trial in Europe

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home September 18, 2023
arrow
Johnson & Johnson today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.
News | Cardiovascular Business
Johnson & Johnson Completes Acquisition of Abiomed

December 22, 2022 — Johnson & Johnson today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now ...

Home December 22, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now